Project information
Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
- Project Identification
- 15-33999A (kod CEP: NV15-33999A)
- Project Period
- 5/2015 - 12/2018
- Investor / Pogramme / Project type
-
Ministry of Health of the CR
- Ministry of Health Research Programme 2015 - 2022
- MU Faculty or unit
- Faculty of Medicine
- Cooperating Organization
-
Institute of Biophysics
- Responsible person Mgr. Karel Souček, Ph.D.
- Responsible person prof. MUDr. Marek Svoboda, Ph.D.
zatím nemáme
Publications
Total number of publications: 18
2018
-
Presence of growth/differentiation factor-15 cytokine in human follicular fluid, granulosa cells, and oocytes
Journal of Assisted Reproduction and Genetics, year: 2018, volume: 35, edition: 8, DOI
-
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations
Year: 2018, type: Conference abstract
-
The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition
Cytometry Part A, year: 2018, volume: 93A, edition: 9, DOI
2017
-
Comparative cell cycle transcriptomics reveals synchronization of developmental transcription factor networks in cancer cells
PLOS ONE, year: 2017, volume: 12, edition: 12, DOI
-
Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Molecular Cancer Therapeutics, year: 2017, volume: 16, edition: 9, DOI
2016
-
Cancer TARGETases: DSB Repair as a Pharmacological Target
Pharmacology & Therapeutics, year: 2016, volume: 161, edition: "May", DOI
-
Checkpoint kinase 1 inhibition potentiates apoptosis and inflicts mitotic failure in CLL-derived MEC-1 cell line.
Year: 2016, type: Conference abstract
-
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells